Cover Image
Market Research Report
Product code 
1121763

Cardiac Safety Services Market by Type (Standalone, Integrated), Services (ECG/Holter measurement, Blood Pressure measurement, Cardiac Imaging, Thorough QT Studies), End User (Pharmaceutical, Biopharma, CROs), Region - Global Forecast to 2027

Published: | MarketsandMarkets | 128 Pages | Delivery time: 1-2 business days

Price

Back to Top
Cardiac Safety Services Market by Type (Standalone, Integrated), Services (ECG/Holter measurement, Blood Pressure measurement, Cardiac Imaging, Thorough QT Studies), End User (Pharmaceutical, Biopharma, CROs), Region - Global Forecast to 2027
Published: August 25, 2022
MarketsandMarkets
Content info: 128 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents

The cardiac safety services market is projected to reach USD 1.0 Billion by 2027 from USD 0.6 Billion in 2022, at a CAGR of 11.2% during the forecast period. The increasing expenditure by pharmaceutical companies, alongside rising government spending is leading has driven the pace of R&D activity in this industry to develop new drugs. This will contribute to the need for numerous preclinical and clinical services during drug development, including cardiac safety evaluation.

"The Blood Pressure Measurement segment accounted for the second largest share of the type of services market in 2021"

Blood pressure monitoring is an essential part of cardiac safety services. Increasing R&D activities and stringent clinical trial regulations make blood pressure measurement a critical parameter from both an efficacy and a safety endpoint. This factor is expected to drive the growth of this market segment.

"The contract research organizations (CROs) accounted for the second largest share of the end user market in 2021"

CROs provide specialized services to pharmaceutical & biopharmaceutical companies at a low cost. As a result, many pharmaceutical & biopharmaceutical companies are outsourcing their drug discovery services to CROs. As cardiac safety services are critical in drug development processes, their adoption is expected to increase with an increase in outsourcing

Laboratory Corporation of America Holdings (US), Koninklijke Philips N.V. (Netherlands), Clario (US), Banook Group (France), IQVIA (US), Biotrial (France), Certara (US), Celerion (US), Medpace (US), Ncardia (Netherlands), Richmond Pharmacology (UK), PhysioStim (France), Shanghai Medicilon (China), Pharmaceutical Product Development (US), and SGS (Switzerland) are some of the major players operating in the market.

"Europe: The second largest share in the cardiac safety services market"

The European market includes Germany, the UK, France, Italy, Spain, and the RoE. It accounted for the second largest market share of the cardiac safety services market. Important considerations include demographic changes, such as the growing incidence of chronic diseases is expected to drive the market growth in the region

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 80% and Demand Side - 20%
  • By Designation: Managers- 45%, CXOs and Director level - 30%, and Executives - 25%
  • By Region: North America -20%, Europe -10%, Asia-Pacific -55%, RoW -15%

List of Companies Profiled in the Report:

  • Laboratory Corporation of America Holdings (US)
  • Koninklijke Philips N.V. (Netherlands)
  • Clario (US)
  • Banook Group (France)
  • IQVIA (US)
  • Biotrial (France)
  • Certara (US)
  • Celerion (US)
  • Medpace (US)
  • Ncardia (Netherlands)
  • Richmond Pharmacology (UK)
  • PhysioStim (France)
  • Shanghai Medicilon (China)
  • Pharmaceutical Product Development (US)
  • SGS (Switzerland)

Research Coverage:

This report provides a detailed picture of the cardiac safety services market. It aims at estimating the size and future growth potential of the market across different segments such as the type, type of service, end user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall cardiac safety services market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, challenges, trends, and opportunities.

Product Code: PH 7455

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • FIGURE 1 CARDIAC SAFETY SERVICES MARKET
  • 1.4 YEARS CONSIDERED
  • 1.5 CURRENCY CONSIDERED
  • 1.6 LIMITATIONS
  • 1.7 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 2 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Key data from primary sources
      • 2.1.2.2 Key industry insights
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 BOTTOM-UP APPROACH
    • FIGURE 4 BOTTOM-UP APPROACH
    • 2.2.2 TOP-DOWN APPROACH
    • FIGURE 5 TOP-DOWN APPROACH
    • 2.2.3 GROWTH FORECAST
  • 2.3 DATA TRIANGULATION
    • FIGURE 6 DATA TRIANGULATION METHODOLOGY
  • 2.4 RESEARCH ASSUMPTIONS

3 EXECUTIVE SUMMARY

    • FIGURE 7 CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2022 VS. 2027 (USD MILLION)
    • FIGURE 8 CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
    • FIGURE 9 CARDIAC SAFETY SERVICES MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    • FIGURE 10 GEOGRAPHICAL SNAPSHOT OF CARDIAC SAFETY SERVICES MARKET

4 PREMIUM INSIGHTS

  • 4.1 CARDIAC SAFETY SERVICES MARKET OVERVIEW
    • FIGURE 11 INCREASING NUMBER OF CLINICAL TRIALS TO DRIVE MARKET GROWTH
  • 4.2 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET SHARE, BY TYPE AND COUNTRY (2021)
    • FIGURE 12 INTEGRATED SERVICES ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2021
  • 4.3 CARDIAC SAFETY SERVICES MARKET SHARE, BY TYPE OF SERVICE, 2022 VS. 2027
    • FIGURE 13 ECG/HOLTER MEASUREMENT SERVICES SEGMENT TO DOMINATE MARKET IN 2027
  • 4.4 CARDIAC SAFETY SERVICES MARKET SHARE, BY END USER, 2022
    • FIGURE 14 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2022
  • 4.5 CARDIAC SAFETY SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 15 EUROPEAN COUNTRIES TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 16 CARDIAC SAFETY SERVICES MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Growing R&D expenditure in pharmaceutical & biopharmaceutical industry
    • FIGURE 17 GLOBAL PHARMACEUTICAL R&D SPENDING, 2012-2026
      • 5.2.1.2 Increased outsourcing of R&D activities
    • FIGURE 18 ACTIVE PHARMACEUTICAL DRUG PIPELINE, JANUARY 2011 TO JANUARY 2021
      • 5.2.1.3 Increasing number of clinical trials
    • FIGURE 19 INCREASING NUMBER OF CLINICAL TRIALS REGISTERED WORLDWIDE (2000-2021)
    • 5.2.2 OPPORTUNITIES
      • 5.2.2.1 Introduction of new technologies and methods
      • 5.2.2.2 Growth in biosimilars and biologics markets
    • 5.2.3 CHALLENGES
      • 5.2.3.1 High cost of cardiac safety evaluation

6 CARDIAC SAFETY SERVICES MARKET, BY TYPE

  • 6.1 INTRODUCTION
    • TABLE 1 CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • 6.2 INTEGRATED SERVICES
    • 6.2.1 INTEGRATED SERVICES TO DOMINATE CARDIAC SAFETY SERVICES MARKET
    • TABLE 2 INTEGRATED CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 3 NORTH AMERICA: INTEGRATED CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 4 EUROPE: INTEGRATED CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 5 ASIA PACIFIC: INTEGRATED CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • 6.3 STANDALONE SERVICES
    • 6.3.1 STANDALONE SERVICES SEGMENT WITNESSING GROWTH DUE TO COST-EFFECTIVENESS
    • TABLE 6 STANDALONE CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 7 NORTH AMERICA: STANDALONE CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 8 EUROPE: STANDALONE CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 9 ASIA PACIFIC: STANDALONE CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)

7 CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE

  • 7.1 INTRODUCTION
    • TABLE 10 CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020-2027 (USD MILLION)
  • 7.2 ECG/HOLTER MEASUREMENT SERVICES
    • 7.2.1 ECG/HOLTER MEASUREMENT SERVICES SUPPORT R&D IN NOVEL METHODS FOR CLINICAL TRIALS AND DRUG DISCOVERY
    • TABLE 11 ECG/HOLTER MEASUREMENT SERVICES MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 12 NORTH AMERICA: ECG/HOLTER MEASUREMENT SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 13 EUROPE: ECG/HOLTER MEASUREMENT SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 14 ASIA PACIFIC: ECG/HOLTER MEASUREMENT SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.3 BLOOD PRESSURE MEASUREMENT SERVICES
    • 7.3.1 INCREASING R&D ACTIVITIES TO DRIVE MARKET GROWTH
    • TABLE 15 BLOOD PRESSURE MEASUREMENT SERVICES MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 16 NORTH AMERICA: BLOOD PRESSURE MEASUREMENT SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 17 EUROPE: BLOOD PRESSURE MEASUREMENT SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 18 ASIA PACIFIC: BLOOD PRESSURE MEASUREMENT SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.4 CARDIOVASCULAR IMAGING SERVICES
    • 7.4.1 CARDIOVASCULAR IMAGING SERVICES HELP IN DRUG EVALUATION
    • TABLE 19 CARDIOVASCULAR IMAGING SERVICES MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 20 NORTH AMERICA: CARDIOVASCULAR IMAGING SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 21 EUROPE: CARDIOVASCULAR IMAGING SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 22 ASIA PACIFIC: CARDIOVASCULAR IMAGING SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.5 THOROUGH QT STUDIES
    • 7.5.1 NEED TO MEET STRINGENT REGULATORY REQUIREMENTS TO DRIVE DEMAND FOR THOROUGH QT STUDIES
    • TABLE 23 THOROUGH QT STUDIES MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 24 NORTH AMERICA: THOROUGH QT STUDIES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 25 EUROPE: THOROUGH QT STUDIES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 26 ASIA PACIFIC: THOROUGH QT STUDIES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.6 OTHER SERVICES
    • TABLE 27 OTHER CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 28 NORTH AMERICA: OTHER CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 29 EUROPE: OTHER CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 30 ASIA PACIFIC: OTHER CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)

8 CARDIAC SAFETY SERVICES MARKET, BY END USER

  • 8.1 INTRODUCTION
    • TABLE 31 CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 8.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
    • 8.2.1 INCREASING R&D BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO DRIVE DEMAND FOR CARDIAC SAFETY SERVICES
    • TABLE 32 CARDIAC SAFETY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 33 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 34 EUROPE: CARDIAC SAFETY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 35 ASIA PACIFIC: CARDIAC SAFETY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.3 CONTRACT RESEARCH ORGANIZATIONS
    • 8.3.1 INCREASING OUTSOURCING OF DRUG DISCOVERY PROCESSES TO SUPPORT SEGMENT GROWTH
    • TABLE 36 CARDIAC SAFETY SERVICES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 37 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 38 EUROPE: CARDIAC SAFETY SERVICES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 39 ASIA PACIFIC: CARDIAC SAFETY SERVICES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020-2027 (USD MILLION)

9 CARDIAC SAFETY SERVICES MARKET, BY REGION

  • 9.1 INTRODUCTION
    • TABLE 40 CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 9.2 NORTH AMERICA
    • FIGURE 20 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET SNAPSHOT
    • TABLE 41 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 42 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020-2027 (USD MILLION)
    • TABLE 43 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 44 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.2.1 US
      • 9.2.1.1 US dominates global cardiac safety services market
    • TABLE 45 US: TOTAL NUMBER OF CLINICAL TRIALS (2019)
    • TABLE 46 US: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020-2027 (USD MILLION)
    • TABLE 47 US: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 48 US: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.2.2 CANADA
      • 9.2.2.1 Canada has high-quality clinical trial infrastructure and expertise
    • TABLE 49 CANADA: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020-2027 (USD MILLION)
    • TABLE 50 CANADA: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 51 CANADA: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 9.3 EUROPE
    • FIGURE 21 EUROPE: CARDIAC SAFETY SERVICES MARKET SNAPSHOT
    • TABLE 52 EUROPE: CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 53 EUROPE: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020-2027 (USD MILLION)
    • TABLE 54 EUROPE: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 55 EUROPE: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.3.1 GERMANY
      • 9.3.1.1 Availability of skilled staff and flexible labor laws have made Germany a popular EU hub for clinical trials
    • TABLE 56 GERMANY: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020-2027 (USD MILLION)
    • TABLE 57 GERMANY: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 58 GERMANY: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.3.2 UK
      • 9.3.2.1 Steady growth of pharmaceutical R&D expenditure indicates favorable prospects for cardiac safety services
    • TABLE 59 UK: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020-2027 (USD MILLION)
    • TABLE 60 UK: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 61 UK: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.3.3 FRANCE
      • 9.3.3.1 High clinical trial activity for cancer therapies to drive market growth
    • TABLE 62 FRANCE: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020-2027 (USD MILLION)
    • TABLE 63 FRANCE: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 64 FRANCE: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.3.4 ITALY
      • 9.3.4.1 Strong pharma industry and availability of funding for drug development fuel market growth
    • TABLE 65 NUMBER OF CLINICAL TRIALS STARTED IN ITALY, BY COMPANY (JANUARY 2021)
    • TABLE 66 ITALY: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020-2027 (USD MILLION)
    • TABLE 67 ITALY: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 68 ITALY: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.3.5 SPAIN
      • 9.3.5.1 Growing investment in pharmaceutical R&D and a favorable climate for approvals boost market growth
    • TABLE 69 SPAIN: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020-2027 (USD MILLION)
    • TABLE 70 SPAIN: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 71 SPAIN: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.3.6 REST OF EUROPE
    • TABLE 72 ROE: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020-2027 (USD MILLION)
    • TABLE 73 ROE: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 74 ROE: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 9.4 ASIA PACIFIC
    • TABLE 75 APAC: CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 76 APAC: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020-2027 (USD MILLION)
    • TABLE 77 APAC: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 78 APAC: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.4.1 CHINA
      • 9.4.1.1 China dominates APAC market for cardiac safety services
    • TABLE 79 CHINA: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020-2027 (USD MILLION)
    • TABLE 80 CHINA: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 81 CHINA: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.4.2 JAPAN
      • 9.4.2.1 Strong IP rights and supportive policies have strengthened R&D sector in Japan
    • TABLE 82 JAPAN: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020-2027 (USD MILLION)
    • TABLE 83 JAPAN: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 84 JAPAN: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.4.3 INDIA
      • 9.4.3.1 Lack of language barriers and availability of trained resources make India an attractive destination for clinical trials
    • TABLE 85 INDIA: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020-2027 (USD MILLION)
    • TABLE 86 INDIA: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 87 INDIA: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.4.4 AUSTRALIA
      • 9.4.4.1 Favorable R&D tax incentives and cash rebates have driven clinical trial activity in Australia
    • TABLE 88 AUSTRALIA: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020-2027 (USD MILLION)
    • TABLE 89 AUSTRALIA: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 90 AUSTRALIA: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.4.5 REST OF ASIA PACIFIC
    • TABLE 91 ROAPAC: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020-2027 (USD MILLION)
    • TABLE 92 ROAPAC: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 93 ROAPAC: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 9.5 REST OF THE WORLD
    • TABLE 94 ROW: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020-2027 (USD MILLION)
    • TABLE 95 ROW: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 96 ROW: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020-2027 (USD MILLION)

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
    • FIGURE 22 KEY GROWTH STRATEGIES ADOPTED BY MARKET PLAYERS FROM 2019-2022
  • 10.2 MARKET PLAYER RANKING
    • TABLE 97 GLOBAL CARDIAC SAFETY SERVICES MARKET PLAYER RANKING, 2021
  • 10.3 COMPETITIVE LEADERSHIP MAPPING
    • 10.3.1 VISIONARY LEADERS
    • 10.3.2 DYNAMIC DIFFERENTIATORS
    • 10.3.3 INNOVATORS
    • 10.3.4 EMERGING COMPANIES
    • FIGURE 23 CARDIAC SAFETY SERVICES MARKET: COMPETITIVE LEADERSHIP MAPPING
  • 10.4 COMPETITIVE SITUATION AND TRENDS
    • 10.4.1 ACQUISITIONS
    • TABLE 98 ACQUISITIONS, 2019-2022
    • 10.4.2 PARTNERSHIPS, ALLIANCES, AND AGREEMENTS
    • TABLE 99 PARTNERSHIPS, ALLIANCES, AND AGREEMENTS, 2019-2022
    • 10.4.3 EXPANSIONS
    • TABLE 100 EXPANSIONS, 2019-2022
    • 10.4.4 OTHER STRATEGIES
    • TABLE 101 OTHER STRATEGIES, 2019-2022

11 COMPANY PROFILES

  • (Business overview, Products offered, Recent Developments, MNM view)**
  • 11.1 KEY PLAYERS
    • 11.1.1 LABORATORY CORPORATION OF AMERICA HOLDINGS
    • TABLE 102 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS OVERVIEW
    • FIGURE 24 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT
    • 11.1.2 KONINKLIJKE PHILIPS
    • TABLE 103 KONINKLIJKE PHILIPS: BUSINESS OVERVIEW
    • FIGURE 25 KONINKLIJKE PHILIPS: COMPANY SNAPSHOT
    • 11.1.3 CLARIO
    • TABLE 104 CLARIO: BUSINESS OVERVIEW
    • 11.1.4 BANOOK GROUP
    • TABLE 105 BANOOK GROUP: BUSINESS OVERVIEW
    • 11.1.5 IQVIA
    • TABLE 106 IQVIA: BUSINESS OVERVIEW
    • FIGURE 26 IQVIA: COMPANY SNAPSHOT
    • 11.1.6 BIOTRIAL
    • TABLE 107 BIOTRIAL: BUSINESS OVERVIEW
    • 11.1.7 CERTARA
    • TABLE 108 CERTARA: BUSINESS OVERVIEW
    • FIGURE 27 CERTARA: COMPANY SNAPSHOT
    • 11.1.8 CELERION
    • TABLE 109 CELERION: BUSINESS OVERVIEW
    • 11.1.9 MEDPACE
    • TABLE 110 MEDPACE: BUSINESS OVERVIEW
    • FIGURE 28 MEDPACE: COMPANY SNAPSHOT
    • 11.1.10 NCARDIA
    • TABLE 111 NCARDIA: BUSINESS OVERVIEW
    • 11.1.11 RICHMOND PHARMACOLOGY
    • TABLE 112 RICHMOND PHARMACOLOGY: BUSINESS OVERVIEW
    • 11.1.12 PHYSIOSTIM
    • TABLE 113 PHYSIOSTIM: BUSINESS OVERVIEW
  • 11.2 OTHER PLAYERS
    • 11.2.1 SHANGHAI MEDICILON
    • 11.2.2 PHARMACEUTICAL PRODUCT DEVELOPMENT LLC.
    • 11.2.3 SGS S.A.
  • *Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

12 APPENDIX

  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3 CUSTOMIZATION OPTIONS
  • 12.4 RELATED REPORTS
  • 12.5 AUTHOR DETAILS